Sort
48,018 grants matching “immunotherapy”
Core C: Patient Derived Xenograft (PDX)/ Syngeneic Mouse Core
$388,439Gatien Moriceau · University Of California Los Angeles · P01 · FY2021 · CA
Role of type 2 immune response in pancreatic cancer tumorigenesis
$388,432Prasenjit Dey · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Regulation of T cell activation and exhaustion by Tim-3
$388,425Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2018 · AI
Akt controls alternative splicing in T helper call fate decisions
$388,425Penelope A Morel · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · AI
Regulation of T cell activation and exhaustion by Tim-3
$388,425Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · AI
Akt controls alternative splicing in T helper call fate decisions
$388,425Penelope A Morel · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · AI
Akt controls alternative splicing in T helper call fate decisions
$388,425Penelope A Morel · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · AI
Regulation of T cell activation and exhaustion by Tim-3
$388,425Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · AI
Regulation of T cell activation and exhaustion by Tim-3
$388,425Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · AI
IRF-8 as a Negative Regulator of CD11b+Gr-1+ Myeloid Cell Production and Function
$388,425Scott I. Abrams · Roswell Park Cancer Institute Corp · R01 · FY2015 · CA
Akt controls alternative splicing in T helper call fate decisions
$388,425Penelope A Morel · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · AI
Pharmacologic Enhancement of Viral Oncolysis
$388,358E. Antonio Chiocca · Massachusetts General Hospital · P01 · FY2007 · CA
Phase I Clinical Trials of Novel Agents
$388,330Sloan-Kettering Institute For Cancer Res · U01 · FY2004 · CA
Comprehensive Assessment of Cancer Immunotherapy Response
$388,323Timothy Perk · Aiq Solutions, Inc. · R43 · FY2020 · CA
Cancer-Associated Fibroblasts Alter the Composition of B cells in Solid Malignancies
$388,303Sandra Orsulic · Cedars-Sinai Medical Center · R01 · FY2019 · CA
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells
$388,292Dayanidhi Raman · University Of Toledo Health Sci Campus · R01 · FY2024 · CA
The role of the CD58:CD2 axis in cancer immune evasion and resistance to immunotherapy
$388,273Benjamin Izar · Columbia University Health Sciences · R01 · FY2024 · CA
Molecular Mechanisms of Immune Tolerance
$388,265Roberta Pelanda · National Jewish Health · T32 · FY2022 · AI
ALLOCHIMERISM FOLLOWING HAPLOIDENTICAL STEM CELL TRANSPL
$388,250University Of Illinois At Chicago · R01 · FY2001 · HL
ALLOCHIMERISM FOLLOWING HAPLOIDENTICAL STEM CELL TRANSPL
$388,250University Of Illinois At Chicago · R01 · FY2000 · HL
ALLOCHIMERISM FOLLOWING HAPLOIDENTICAL STEM CELL TRANSPL
$388,250University Of Illinois At Chicago · R01 · FY2002 · HL
Solid-state nanopores and silicon nanomembranes for ultrasensitive protein biomarker detection
$388,198James L McGrath · University Of Rochester · R01 · FY2022 · EB
Nucleic acid modulators and theranostics for ADAR
$388,125Guizhi Zhu · Virginia Commonwealth University · R35 · FY2021 · GM
T cell costimulation and regulation in myocarditis
$388,120Andrew H Lichtman · Brigham And Women'S Hospital · R01 · FY2006 · HL
MYC activation in tumor progression of neuroblastoma
$388,113Min Hee Kang · Texas Tech University Health Scis Center · R01 · FY2021 · CA